On Monday 17 November 2014 we launched our latest report, Healthcare and Life Sciences Predictions 2020, at the FT Global Pharmaceuticals and Biotechnology Conference 2014 in London. This report is markedly different to our usual reports which are typically evidenced based with deep dives into specific issues. Instead, in this forward look, we provide a deliberately challenging view of what the industry might look like in 2020. The report is based on insights drawn from primary research, desk research and our day to day interactions with clients and key stakeholders across the sector, and utilises the breadth and depth of our experience across our global network. Two cross-cutting themes link the ten predictions, the revolutionary potential for digital technology and the evolutionary influence of patient power.
In May 2014, Public Health England and the Alzheimer’s Society, as part of the Prime Ministers Dementia Challenge, joined forces to launch a new campaign to encourage people to become Dementia Friends. Dementia Friends is a social movement which aims to create one million "Dementia Friends" by 2015. Currently there are over 500,000 Dementia Friends in the UK. This week, Deloitte’s entire Executive became Dementia Friends and, in leading by example, hope to boost the number by encouraging other Deloitte employees, and hopefully their clients, to follow suit.
My interest in finding out more about Ebola was sparked by colleagues writing for the US Center for Health Solutions - The Ebola outbreak: A call to action for a translational approach to R&D.[i] This article contrasts the traditional approach to pharmaceutical research and development (R&D)- which can typically take 17 to 23 years to bring a new drugs to market - with a more translational approach to R&D which makes more effective use of the exponential rise of big data and analytics and speeds up the time of the whole process.
This week, my Deloitte public sector colleagues, together with the think tank Reform, published their third annual report: State of the State 2014-15: Government’s inflection point. Based on an analysis of public data, augmented with information from roundtable discussions and interviews with senior executives across the public sector, the report presents a snapshot of the pressures on government finances and the challenges facing public services today and over the next five years.
The much anticipated report, the NHS Five Year Forward View[i], launched today by Simon Stevens, the Chief Executive of NHS England, developed through consultation with key stakeholders, including patient groups.[ii]
On the 8 September Public Health England launched its latest Stoptober campaign aimed at encouraging people across the country to stop smoking from the 1 October for 28 days (and beyond). Evidence shows that if a smoker can stop for 28 days they are five times more likely to stay smoke-free. The campaign is supported by local NHS Stop Smoking Services, Local Authorities, pharmacies, retailers and large employers. This support is backed by a national TV, radio, press and online campaign running for 6 weeks. So most people are likely to have heard about it – but what’s the evidence base, how does it work and why is it necessary?
In England, at least £4.5 billion a year is spent caring for people who are at the end-of-life, and while some individuals, particularly those accessing hospice or specialist community and hospital palliative services, receive high standards of care many others do not. Our report, Transforming care at the end-of-life, argues that while there has been a great deal of positive activity following the Department of Health’s 2008 End-of-life Care Strategy, there are still too many inequalities in access to support and availability of good quality care.
Mental health is regularly referred to as the ‘Cinderella of all NHS Cinderella services’. In recognition of this, the coalition Government’s 2011 outcomes strategy No Health Without Mental Health, set out plans to improve people’s mental health and wellbeing.
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our consultants in health care and life sciences:
The life science industry is facing significant challenges such as patent cliffs, pricing and market access restrictions as well as increasing regulatory pressure. These challenges fundamentally call into question traditional business models and, as a result, life science companies are increasingly looking to new and innovative ways to tackle these challenges
In 2007, the National Audit Office’s (NAO) report “Improving services and support for people with dementia” drew Parliament’s attention to the fact that dementia presented a significant and urgent challenge to health and social care in terms of the numbers of people affected (at least 560,000 people in England) and the costs (some £14.3 billion a year, including direct costs to the NHS and social care of £3.3 billion a year). New figures out this month suggest that the challenge is even bigger.
In recent months, many health and social care commentators have called for a fundamental reform of care funding. While there has been much debate about some of the proposed solutions, there has been limited information or financial modelling on the cost and impact of the different options.